Revance

Where Revance fits

Revance is the injectables vendor you add when you want your menu to say something the big three can't. Acquired by Crown Laboratories in February 2025 for roughly $924 million and still operating under its own name, Revance fields a two-product portfolio with unusually sharp positioning. Daxxify, FDA-approved in 2022, is the first and only neurotoxin stabilized with a proprietary peptide rather than human serum albumin, and it carries the category's strongest duration claim — a median of about six months in pivotal glabellar trials, roughly double the conventional toxin cadence. The RHA Collection, Teoxane's 'resilient hyaluronic acid' fillers distributed by Revance in the US, is the only HA filler line FDA-approved for dynamic facial wrinkles, engineered to stretch with expression rather than resist it; 2025 brought RHA formulations with mepivacaine for a more comfortable injection experience.

What stands out

• The duration story. Daxxify's six-month median gives practices a legitimate 'twice-a-year toxin' pitch. For patients who dread the quarterly appointment treadmill, it is the most compelling differentiation any toxin has offered in years — and it supports premium per-treatment pricing.
• RHA's dynamic-wrinkle labeling. No other HA filler line can make the FDA-cleared dynamic-wrinkle claim. In the hands of skilled injectors, RHA products excel in mobile areas — perioral lines, expressive mid-face — where stiffer gels can look frozen or migrate. The mepivacaine line extension is a small but real patient-comfort win.
• Clean-label formulation. The peptide-stabilized, albumin-free Daxxify formulation resonates with the same ingredient-conscious patients who respond to Xeomin's 'naked' story, with a duration benefit layered on top.
• Premium-menu economics. Both products let practices charge for outcomes rather than compete on per-unit price — a healthier margin posture than discounting commodity toxin units.

Where it falls short

• Challenger scale. Rep coverage is thinner than Allergan's, Galderma's or Merz's, loyalty and co-marketing infrastructure is far smaller than Allē or ASPIRE, and account support can feel stretched outside major metros. Onboarding is solid but not white-glove everywhere.
• Cost and expectation management. Daxxify vials command a premium, and real-world duration varies — a meaningful minority of patients land closer to four months than six. Practices must price per-month-of-effect, set expectations carefully, and train front desks on the conversation, or the duration pitch can backfire into refund requests.
• Post-acquisition uncertainty. The Crown Laboratories deal stabilizes Revance's finances, but practices report the usual transition noise: program tweaks, rep turnover and evolving rewards mechanics. Confirm current terms at account opening.
• Not a full shelf. Two product families cannot anchor an entire injectables menu; Revance is a complement to a big-three account, not a substitute.

Who should choose it

Choose Revance if you are an injector-led or established med spa competing on outcomes and experience rather than price, with a patient base of aesthetic veterans willing to pay for fewer visits and natural movement. Daxxify works best as a premium tier above your baseline toxin, and RHA as the specialist option for expressive areas. New practices building a first shelf should start with a big-three account and add Revance once volume and pricing discipline are established. A licensed prescriber or medical director is required, and buyers should pressure-test rep coverage in their territory and the current state of rewards programs under Crown ownership before committing volume.